GSK’s human monoclonal antibody Benlysta (belimumab) has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to treat adult patients with systemic lupus erythematosus (SLE), a chronic, incurable, autoimmune disease.
The European Commission (EC) has granted marketing authorisation for Sanofi and Regeneron Pharmaceuticals’ Dupixent (dupilumab) to treat adults with moderate to severe atopic dermatitis (AD), a form of eczema.
The US Food and Drug Administration (FDA) has agreed to review Eisai’s application for an additional indication of Lenvima (lenvatinib mesylate) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC).
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox